info@flamel.com
 
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
Archives


Latest News

March 8, 2010
Flamel Technologies Announces Fourth Quarter and Year-End 2009 Results


A conference call to discuss the earnings is scheduled for 8:30 AM EST on March 09, 2010.
The dial-in number (for investors in the U.S. and Canada) is 1-877-857-6173; the conference ID number is 2453008.
International investors are invited to dial 1 719-325-4888.
Webcast

March 1, 2010
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call

December 18, 2009
Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection

November 16, 2009
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million
A conference call to discuss earnings is scheduled for 8:30 AM EST November 16, 2009.
The dial-in number (for investors in the U.S. and Canada) is 1-800-860-2442; the conference ID number is 435349.
International investors are invited to dial 1 412-858-4600.
Webcast

November 04, 2009
Flamel Technologies Announces Licensing Agreement with Pfizer

September 18, 2009
Flamel Technologies to Present at UBS Global Life Sciences Conference

Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Micropump® Technologies
From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info

November 1, 2006
Flamel Technologies Announces Third Quarter Results

October 23, 2006
Flamel Technologies Welcomes FDA Approval of COREG CR™

October 20, 2006
FDA Approves New, Once-a-Day COREG CR(TM) for the Treatment of Three Key Cardiovascular Conditions

July 31, 2006
Flamel Technologies Announces Second Quarter Results
Conference Call: Tuesday August, 1st, at 8:30 AM EDT
US: 800-374-1498
Int'l: +1-706-634-7261
ID: 3668963
Webcast

June 12, 2006
Flamel Technologies Announces Results of Annual Meeting

May 19, 2006
Flamel Technologies Announces Receipt of Milestone from GlaxoSmithKline

May 4, 2006
Flamel Technologies Announces that RHEI Pharmaceuticals has Licensed Flamel's ASACARD® (Controlled-Release Aspirin) for China and Taiwan

May 3, 2006
Flamel Technologies Announces First Quarter Results
Conference Call: Thursday May, 4th, at 8:30 AM EDT
US: 800-374-1498
Int'l: +1-706-634-7261
ID: 8474990

April 24, 2006
Flamel Technologies Announces Projected Release Date of First Quarter Results
and Conference Call
Conference Call: Thursday May, 4th, at 8:30 AM EDT
US: 800-374-1498
Int'l: +1-706-634-7261
ID: 8474990

March 7, 2006
Flamel Technologies Announces Fourth Quarter and Year-End Results
Conference Call Webcast
Conference Call Replay
Until March 22
US: 800-642-1687
Int'l: +1-706-645-9291
ID: 6135376

March 2, 2006
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results, Conference Call

January 11, 2006
Flamel Technologies Announces Appointment of Lodewijk J.R. de Vink to its Board of Directors